NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

HyGro,

Thanks for posting, but you are misinformed. Nobody ever announced who is going to partner with or acquire the company for sure—nobody has that kind of insider foreknowledge. You seem to be the only one who knows with certainty 😶

Fact ✅️: Merck is currently among those supporting the ongoing combo research at UCLA.

The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.

https://clinicaltrials.gov/ct2/show/NCT04201873

*FDA recommends that the control group participants be provided the current SOC (best known therapy).
https://www.fda.gov/media/120721/download

In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.

The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not generated evidence of safety and efficacy.



Dr. Toms also briefly mentioned the PD1 research during the press conference about the P3:
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/


https://www.nature.com/articles/s41420-023-01782-7

https://www.jci.org/articles/view/169314